First human receives cellular reprogramming therapy in landmark anti-aging clinical trial

Jun 9, 2026

In a landmark clinical trial, the first human patient has received a cellular reprogramming therapy from Life Biosciences aimed at reversing aging. The injection, targeting glaucoma, uses a partial version of Nobel-winning 'Yamanaka Factors' to make old cells young again. While backed by major investors like Jeff Bezos and Eli Lilly, the field faces significant safety hurdles, including cancer risks, which the trial attempts to mitigate.

First human cellular reprogramming trial

▪The initial FDA trial, ER-100, is recruiting just under 20 patients with glaucoma or NAION, a common cause of sudden vision loss.
▪Boston-based biotech startup Life Biosciences announced on June 9, 2026, that the first patient has been dosed in a human trial for a cellular reprogramming therapy.
▪The first patient received the injection in one eyeball and will be monitored for six months for safety and efficacy.
▪The trial is testing a therapy for glaucoma, a disease that can cause blindness by damaging the optic nerve.

Yamanaka factors epigenetic reprogramming

▪Epigenetic reprogramming is a technique that aims to make old cells behave as if they were young again.
▪A 2020 study found that activating three of these genes in mice with damaged optic nerves promoted neuron regeneration and reversed vision loss.
▪The goal of "partial reprogramming" is to restore youthful features to aged cells without reverting them to an undifferentiated stem-cell state.
▪The concept is based on "Yamanaka Factors," four proteins discovered in 2007 by scientist Shinya Yamanaka that can reprogram adult cells.

Pharmaceutical industry investment surge

▪Pharmaceutical giants Eli Lilly and Merck are also investing in the field of cellular reprogramming.
▪Billionaires Jeff Bezos and Sam Altman are funding cellular reprogramming startups Altos Labs and Retro Biosciences.
▪Eli Lilly recently participated in a $435 million funding round for New Limit, another biotech startup focused on cellular reprogramming.

Cancer risk safety concerns

▪The therapy is controlled by a pill-based on/off switch; patients take the antibiotic doxycycline to activate it.
▪The Life Biosciences therapy uses only three of the four Yamanaka factors, skipping the one most associated with cancer.
▪In some animal studies, cellular reprogramming has caused cancerous tumors to develop in mice.
▪A major safety concern is the risk of cancer, as two of the four Yamanaka factors are oncogenes that can cause cells to divide indefinitely.
▪The eye is considered a relatively safe starting point for the trial because it is semi-protected from the rest of the body.

Potential systemic aging applications

▪Any systemic drug using this technology is likely more than a decade away from being approved by the FDA.
▪If successful, the technology could lead to systemic therapies that rejuvenate cells in tissues like muscle, liver, and neurons.